Ranitidine prescription capsules recall - Avkare Pharmaceuticals

November 21, 2019

On October 25, 2019, Avkare Pharmaceuticals issued a voluntary recall of prescription ranitidine capsules manufactured by Dr. Reddy’s and distributed by AvKare Pharmaceuticals due to an elevated amount of an unexpected impurity (NDMA) found in the active pharmaceutical ingredient.

Express Scripts will send a letter to patients who have received medication impacted by the recall.

The FDA recommends speaking with your prescriber if you want to stop your medication or use an alternative medication.

 

Product Description

NDC#

Ranitidine 150mg Capsules

42291-0735-50

Ranitidine 300mg Capsules

42291-0736-50

 

Additional information is available on the FDA’s website: 

https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine

Last updated: November 21, 2019

The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.